Brazil’s health regulator has given the green light to the Oxford/AstraZeneca and Chinese-made Sinovac coronavirus vaccines, paving the way for Latin America’s largest nation to begin an immunisation programme that has been marred by delays and political bickering.
巴西衛(wèi)生監(jiān)管機構已批準分別由牛津/阿斯利康(Oxford/AstraZeneca)和中國公司科興(Sinovac)研發(fā)的兩款新型冠狀病毒肺炎(COVID-19,即2019冠狀病毒病)疫苗,為這個拉美最大國家啟動疫苗接種計劃鋪平了道路。巴西的疫苗接種計劃已多次延遲,在政治上也引發(fā)了爭吵。
您已閱讀12%(408字),剩余88%(3061字)包含更多重要信息,訂閱以繼續(xù)探索完整內容,并享受更多專屬服務。